Alterity Therapeutics (ATHE) vs Aytu BioPharma (AYTU)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Aytu BioPharma (AYTU) has outperformed Alterity Therapeutics (ATHE) over the past year, gaining 32.3% versus a loss of 56.7%. Over five years, ATHE leads with a -85.4% price change compared with -93.2% for AYTU. Alterity Therapeutics is the larger company by market cap ($29.0 million vs $28.9 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ATHE | AYTU |
|---|---|---|
| Share price | $1.52 | $2.66 |
| Market cap | $29.02M | $28.91M |
| 1-day change | -8.16% | 0.00% |
| YTD return | -50.65% | +2.31% |
| 1-year return | -56.70% | +32.34% |
| 5-year return | -85.38% | -93.21% |
| Forward P/E | — | 17.16 |
| EPS (TTM) | $-0.90 | $-1.78 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $57.57M |
| Revenue growth (YoY) | — | -13.27% |
| Net income (latest FY) | — | $-14.25M |
| Gross margin | — | 63.95% |
| Operating margin | — | -14.44% |
| Net margin | — | -24.76% |
| 52-week high | $5.89 | $3.07 |
| 52-week low | $1.52 | $1.75 |
| Distance from 52-week high | -74.19% | -13.36% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +771.71% | +263.53% |
| Average volume | 89.63K | 141.18K |
| Shares outstanding | 19.09M | 10.87M |
| Employees | 11 | 75 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- AYTU has outperformed ATHE by 89.0 percentage points over the past year.
About Alterity Therapeutics
ATHE stock →Alterity Therapeutics Limited is engages in research and development of Parkinsonian and neurodegenerative disorders, including Multiple System Atrophy (MSA) and Parkinson's disease. The company's lead drug candidate is ATH434, a small molecule drug candidate that has completed Phase II clinical trial for the treatment of Parkinson's disease.
Health Care · Biotechnology: Pharmaceutical Preparations · 11 employees
About Aytu BioPharma
AYTU stock →Aytu BioPharma, Inc., a pharmaceutical company, focuses on commercializing novel therapeutics in the United States and internationally. The company offers prescription products for the treatment of attention deficit hyperactivity disorder (ADHD), including Adzenys XR-ODT extended-release orally disintegrating tablets for patients from six years of age and above; Cotempla XR-ODT A central nervous system stimulant indicated for the treatment of ADHD in patients 6 to 17 years of age; and Metadate CD, a central nervous system stimulant indicated for the treatment of ADHD in patients 6 to 15 years of age.
Health Care · Biotechnology: Pharmaceutical Preparations · 75 employees
ATHE vs AYTU FAQ
Which is bigger, Alterity Therapeutics or Aytu BioPharma?
Alterity Therapeutics (ATHE) is larger, with a market capitalization of $29.02M compared with $28.91M for Aytu BioPharma (AYTU).
Which stock has performed better over the past year, ATHE or AYTU?
AYTU returned +32.34% over the past 12 months, compared with -56.70% for ATHE (price return, excluding dividends). Past performance does not predict future results.
Are Alterity Therapeutics and Aytu BioPharma in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.